Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management

F1000Res. 2015 Jul 6;4(F1000 Faculty Rev):183. doi: 10.12688/f1000research.6189.1.

Darlene K Taylor ¹, Kristine Holthouser ², James H Segars ³, Phyllis C Leppert ⁴

Affiliations

1 Department of Chemistry, North Carolina Central University, Durham, NC, 27707, USA.
2 Department of Obstetrics and Gynecology, University of Louisville, Louisville, KY, USA.
3 Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
4 Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC, 27710, USA.

PMID: 26236472 DOI: 10.12688/f1000research.6189.1

Abstract

Uterine leiomyomas (fibroids) are the most prevalent medical problem of the female reproductive tract, but there are few non-surgical treatment options. Although many advances in the understanding of the molecular components of these tumors have occurred over the past five years, an effective pharmaceutical approach remains elusive. Further, there is currently no clinical method to distinguish a benign uterine leiomyoma from a malignant leiomyosarcoma prior to treatment, a pressing need given concerns about the use of the power morcellator for minimally invasive surgery. This paper reviews current studies regarding the Molecular Biology of uterine fibroids, discusses non-surgical approaches and suggests new cutting-edge therapeutic and diagnostic approaches.

Keywords

fibroids; gynecological cancers; leiomyoma; uterine fibroids; uterine leiomyoma.

Name
Email *

	Sorry, but the email address you supplied was invalid.